NASDAQ:PRAH - PRA Health Sciences Stock Price, Price Target & More

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) posted its quarterly earnings data on Wednesday, April, 25th. The medical research company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.84 by $0.01. The medical research company had revenue of $701.80 million for the quarter, compared to analyst estimates of $694.73 million. PRA Health Sciences had a net margin of 4.07% and a return on equity of 23.06%. PRA Health Sciences's quarterly revenue was up 43.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.62 earnings per share. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $4.00-4.15 for the period, compared to the Thomson Reuters consensus estimate of $4.12. The company issued revenue guidance of $2.84-2.95 billion, compared to the consensus revenue estimate of $2.91 billion.

10 brokers have issued 12-month price objectives for PRA Health Sciences' shares. Their forecasts range from $86.00 to $115.00. On average, they expect PRA Health Sciences' share price to reach $97.80 in the next twelve months. This suggests that the stock has a possible downside of 4.6%. View Analyst Ratings for PRA Health Sciences.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

PRA Health Sciences saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 2,898,254 shares, a decrease of 31.5% from the June 15th total of 4,229,589 shares. Based on an average daily trading volume, of 1,135,267 shares, the short-interest ratio is presently 2.6 days. Currently, 4.5% of the company's shares are short sold. View PRA Health Sciences' Current Options Chain.

Some companies that are related to PRA Health Sciences include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS) and Eloxx Pharmaceuticals (ELOX).

(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Media headlines about PRAH stock have trended somewhat positive on Sunday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. PRA Health Sciences earned a media sentiment score of 0.24 on Accern's scale. They also gave media headlines about the medical research company an impact score of 44.90 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

PRA Health Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include NN Investment Partners Holdings N.V. (0.48%), Scout Investments Inc. (0.12%), Fred Alger Management Inc. (0.10%), Bellecapital International Ltd. (0.10%), Retirement Systems of Alabama (0.10%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Bank of Montreal Can, NN Investment Partners Holdings N.V. and Scout Investments Inc.. Company insiders that have sold PRA Health Sciences company stock in the last year include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was acquired by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Bellecapital International Ltd., Louisiana State Employees Retirement System, Municipal Employees Retirement System of Michigan, First National Bank of Hutchinson, State of Alaska Department of Revenue, Amalgamated Bank and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $102.52.

PRA Health Sciences has a market capitalization of $6.57 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]